ATE306910T1 - Tablette mit verlängerter wirkstoffabgabe im magen - Google Patents

Tablette mit verlängerter wirkstoffabgabe im magen

Info

Publication number
ATE306910T1
ATE306910T1 AT98401956T AT98401956T ATE306910T1 AT E306910 T1 ATE306910 T1 AT E306910T1 AT 98401956 T AT98401956 T AT 98401956T AT 98401956 T AT98401956 T AT 98401956T AT E306910 T1 ATE306910 T1 AT E306910T1
Authority
AT
Austria
Prior art keywords
stomach
tablet
extended release
granules
drug
Prior art date
Application number
AT98401956T
Other languages
English (en)
Inventor
Yves Bonhomme
Geoffroy Nicholson
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Application granted granted Critical
Publication of ATE306910T1 publication Critical patent/ATE306910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98401956T 1998-07-30 1998-07-30 Tablette mit verlängerter wirkstoffabgabe im magen ATE306910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98401956A EP0976395B1 (de) 1998-07-30 1998-07-30 Tablette mit verlängerter Wirkstoffabgabe im Magen

Publications (1)

Publication Number Publication Date
ATE306910T1 true ATE306910T1 (de) 2005-11-15

Family

ID=8235460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98401956T ATE306910T1 (de) 1998-07-30 1998-07-30 Tablette mit verlängerter wirkstoffabgabe im magen

Country Status (8)

Country Link
EP (1) EP0976395B1 (de)
AT (1) ATE306910T1 (de)
AU (1) AU5731899A (de)
DE (1) DE69831940T2 (de)
DK (1) DK0976395T3 (de)
ES (1) ES2249816T3 (de)
SI (1) SI0976395T1 (de)
WO (1) WO2000006129A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1510208A1 (de) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
ES2247897B1 (es) * 2003-12-18 2007-05-01 Gat Formulation Gmbh Tabletas con matriz polimerica emulsionada para emision controlada de gases y procedimiento para su fabricacion.
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
BRPI0615410A2 (pt) * 2005-08-30 2013-02-13 Nicholas Piramal India Ltd composiÇço farmacÊutica de liberaÇço prolongada de metformina e processo para produÇço da mesma
EP1945190A1 (de) * 2005-09-22 2008-07-23 Swissco Devcelopment AG Sprudelnde metformin-zusammensetzung und daraus hergestellte tabletten und granulate
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2361615A1 (de) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Tablette mit verlängerter Dipyridamolfreisetzung
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
WO2013115744A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin)
WO2013115745A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin)
DE102014008685A1 (de) * 2014-06-13 2015-12-17 Lorenz Meinel Freisetzungssystem für therapeutisches Gas
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
WO2025226875A1 (en) * 2024-04-24 2025-10-30 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation

Also Published As

Publication number Publication date
AU5731899A (en) 2000-02-21
DE69831940T2 (de) 2006-04-20
SI0976395T1 (sl) 2006-04-30
DK0976395T3 (da) 2005-11-14
EP0976395B1 (de) 2005-10-19
ES2249816T3 (es) 2006-04-01
EP0976395A1 (de) 2000-02-02
DE69831940D1 (de) 2006-03-02
WO2000006129A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
ATE264666T1 (de) Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
DE69918310D1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
AU2001287892A1 (en) Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
DK1083879T3 (da) Indretninger til at tilvejebringe forlænget medikamentterapi
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
IL159766A0 (en) A sustained release oral dosage form of a hydromorphone
AU6517496A (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
ATE460942T1 (de) Exendine zur glucagon suppression
PT795324E (pt) Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
ES2196381T3 (es) Comprimidos chupables para liberacion modificada de principios activos en el tracto gastrointestinal.
BG108516A (en) Pharmaceutical formulation
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
ZA200003511B (en) Pharmaceutical tablet comprising an nsaid and misoprostol.
DK1206257T3 (da) Anvendelse af aminosyrer til fremstilling af lægemidler, der er beregnet til behandling af insulinresistens
ES2189739T3 (es) Composiciones de betahistina de liberacion controlada.
ATE219665T1 (de) Dosisformen und deren verwendungen
WO2003096968A3 (en) Oral osmotic controlled drug delivery system
DE69513632D1 (de) Mikrogranulate enthaltend 5-nitroimidazolderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0976395

Country of ref document: EP